

Index



A

Abscess, 292
Accreditation, 370
Acidity, vaginal, 100
Acinic cell carcinoma, 288, 305
Actinomyces sp., 99, 104, 138, 144
Adenocarcinoma in situ/endocervix, 84, 95, 96, 100, 113
Adenocarcinoma. *see also* specific organs; specific types
 bronchogenic type, 138, 180, 293
 effusion, 175
 EM characteristics, 350
 esophageal brushing, 138
 metastatic, 174
 poorly differentiated, 97, 175, 199, 201, 203, 310
 recurrent, postradiation, 89
 secretory, 94
 well-differentiated, 94, 203, 299
Adenoid cystic carcinoma, 241, 287, 304
Adenomyosis, 104
Adenosis, vaginal, 93, 98, 100, 103
Adenosquamous carcinoma, 94, 138
Adrenal glands, 9, 177
Air drying, 102
Alcian blue, 175, 245
Alcohol, protein coagulation, 322
Alcoholic cirrhosis, 198
Alkaline phosphatase, 347, 349
Alkalinity, vaginal, 100
Allowable error, 364
Alpha-fetoprotein, 4, 92, 308, 351, 352
Alternaria sp., 143
Amenorrhea
 primary, 100
 secondary, 79

Amine precursor uptake and decarboxylation (APUD) tumors, 92, 93, 137, 142, 199
Aminopeptidase, 347
Anaplastic carcinoma, 290
Angiosarcoma, 295
Anisocytosis, 79, 96
Apocrine cells, 240, 245, 247
Argentaffin, 199, 349
Arias-Stella reaction, 96
ASCCP guidelines, 347, 377, 381
Aspergillus sp. 137, 142, 309
Aspiration of necrotic center, 291, 307
Aspiration pneumonia, 141, 294
Asthma, 141, 142, 145
Atrophic vaginitis, 107, 334
Atrophy, 85, 99
Atypia of atrophy, 85, 105, 337
Atypia of atrophy and maturity, 85, 105
Atypical glandular cells of undetermined significance (AGUS), 86, 95, 113
Atypical squamous cells of undetermined significance (ASC-US), 78, 80, 90, 98, 105, 112, 113, 337, 347

B

B cells, monoclonal origin, 300
Bacillus vaginatus, 80
Bacterial infections, *see* Abscess
Balloon cells, 89
Barrett esophagus, 201, 203
Bartholin gland, 87, 94
Basal bodies, 5
Basal cell adenoma, 303
Benign cellular components, 4
Bethesda (2001) system, 78, 88, 90, 12, 377-381
Bicornate uteri, 82
Biebrich-Scarlet stain, 350

Biliary ducts, normal, 298
Blastomyces dermatitidis, 137, 143, 146
Blood, 170
Bone marrow, 145
Bowenoid papulosis, 97
Bowen disease, 81
Branchial cleft cyst, 288
Breast
 adenocarcinoma, 174, 242, 300
 inflammatory carcinoma, 169, 240
 lobular adenocarcinoma, 139
 metastatic adenocarcinoma, 305
 metastatic carcinoma, 172, 182, 302, 353
Brenner tumor, 297
Bronchial cells
 multinucleated, 145
 normal, 146
 reactive, 144, 147, 294
 reactive/reparative changes, 140
Bronchial hyperplasia, 141, 142
Bronchioloalveolar adenocarcinoma, 131, 143, 290
Bronchogenic adenocarcinoma, 138, 144, 350
Burkitt lymphoma, 181, 301, 302, 307

C

Calcitonin, 5
Calymmatobacterium granulomatis, 87
Candida sp. 77, 98
 diabetics and, 82, 100
 esophageal brushing, 205
 oral cavity contamination, 144
 Torulopsis glabrata vs., 78
Carbohydrate moieties, 348
Carcinoembryonic antigen (CEA), 5, 173, 175, 198, 203
Carcinoid tumors, 138, 143, 199, 242, 291, 352

Carcinomas, 111, 240. *see* specific organs; specific type

Carcinoma in situ
 cervical, 90, 101, 105
 chromatin distribution, 101, 112
 cytologic identification, 101
 histology, 94

Carnoy fixative, 294

Cat-scratch disease, 302, 306

CD 5, 299

CD15, 4

Cell streaming, 335

Cell cycle, 5

Cervical intraepithelial neoplasia (CIN), 90, 110, 111

Charcot-Leyden crystals, 141

Chemoluminescent substrate, 349

Chlamydia trachomatis, 90, 94, 97

Cholangiocarcinoma, 286, 295, 308

Chondroblastoma, 294

Chondrocalcinosis, 169

Chondrosarcoma, 81, 93, 295

Choriocarcinoma, 169

Chromatin
 in carcinoma, 79, 80
 coarse, 4, 79, 94, 99, 107, 112
 irregular distribution, 4, 79, 80, 94, 101, 106

Chromogranin, 143, 308, 309, 353

Chromosomes, 4, 5

Chronic granulocytic leukemia, 4

Chronic lymphocytic cervicitis, 101

Chylous effusions, 176

Ciliocytophthoria, 141, 146

Cirrhosis, 290
 endometrial, 93, 97
 vaginal, 97

Clear cell renal carcinoma,

Clinical Laboratory Improvement Amendments of 1988 (CLIA '88), 369

Coccidioides immitis, 139, 144

Cocklebur, 82

Colloid carcinoma, 240, 241, 245

Colloid goiter, 286, 305

Colon
 adenocarcinoma, 138, 176
 adenocarcinoma, metastatic, 84
 metastatic carcinoma, 84, 294, 303, 338

Colorectal carcinoma, 298

Colposcopy, 347, 352, 379, 380

Common acute lymphocytic leukemia antigen, 301

Common leukocyte antigen. *see* Leukocyte common antigen

Condyloma acuminata. *see* Human papillomavirus (HPV)

Corpora amylacea, 142, 144

Corpus albicans, 77

Corpus luteum, 77, 83

Cowdry type A inclusions, 99

Craniopharyngioma, 172

Credentialing, 364

Creola bodies, 141

Cryptococcus neoformans, 138, 143, 146, 170, 173, 177

Curschmann spirals, 140, 141

Cushing syndrome, 110

Cystadenocarcinoma, 94, 136, 181

Cystic hyperplasia, 85

Cystic teratoma, mature, 296

Cytomegalovirus (CMV)
 bronchioloalveolar lavage, 138
 cervical scrape, 94, 98
 FNA, 296

D

Decontamination, 321

Del Castillo syndrome, 88, 110

de Quervain thyroiditis, 289

Desmin, 348

Diabetes mellitus, 80, 82, 85, 100

Diathesis, 79, 90, 92, 98

Diethylstilbestrol (DES), 76, 93, 97, 103

Dilatation and curettage, 82

Döderlein bacillus. *see* *Lactobacillus acidophilus*.

Donovan bodies, 87

Drunken honey comb cells, 302

Ductal adenocarcinoma, 242, 245, 302, 308

Ductal atypia, 240

Ductal carcinoma, infiltrating, 246

Ductal carcinoma in situ (DCIS), 240, 241

Ductal dilation, 243

Ductal lining cells, 245

Duodenum, adenocarcinoma, 199, 202

Dysgerminoma, 296

Dyskeratocytes, 85, 90

Dyskeratosis, 85

Dysphagia, long-standing, 204

E

EA stains, 322, 323

Echinococcus granulosus, 174, 175, 290, 308

Elementary bodies, 97

Endocervical adenocarcinoma in situ (AIS)
 chromatin, 96
 differentiation from CIS, 95, 106
 differentiation from ECA, 95, 377
 in liquid-based cytology, 337
 pleomorphism, 106
 rosettes, 106

Endocervical adenocarcinoma (ECA)
 cellular morphology, 84, 86, 95, 114
 cervical/endocervical smears, 80, 81
 differentiation from AIS, 84, 86, 96
 metastatic, 336

poorly differentiated, 81

Endocervical area, 102

Endocervical columnar dysplasia, 96

Endocervical components, 102

Endocervical glandular dysplasia, 86, 94

Endocervical reserve cells, 89

Endocervical columnar dysplasia, 96

Endometrial adenocarcinoma, 80, 83, 337
 basophilic watery diathesis, 80, 83, 101
 clear cell, 93
 grade I, 102, 104
 mucinous, 85, 97
 nucleoli, 84
 poorly differentiated, 87, 97

Endometrial cells, 102, 105, 106

Endometrial hyperplasia, 80, 85, 103

Endometrial polyps, 86

Endometrial stromal cells, 103

Endometrial stromal sarcoma, 95, 338

Endometrioid endocervical adenocarcinoma (EEA), 86, 97

Endometriotic cysts, 297

Endometrium, normal cells, 105

Eosinophilic granuloma, 296

Ependymoma, 170

Epidermoid cysts, 289

Epithelioid histiocytes, 4

Erosion, uterine cervix, 102

Esophageal reflux, chronic, 204

Estrogen therapy
 low-dose, 89
 prognostic information, 78
 squamous metaplasia, 104
 unopposed stimulation, 100, 104

Ethanol, 319, 324

Ewing sarcoma, 169

Exophytic lesions, 107

Exponential smoothing, 371

F

Factor VIII, 348

Fallopian tubes, adenocarcinoma, 102

Fat necrosis, 244, 246

Federal Labor Relations Authority, 366

Ferruginous bodies, 141

Fetal death in utero, 109

Feulgen reaction, 352

Fibroadenoma, 243, 247

Fibrocystic disease (FCD), 243, 244, 245, 247

Fibroma, 295

Fibrous histiocytoma, 296, 307

Fine-needle aspiration (FNA)
 methods, 320

Fixation time, 322

Fixatives. *see* specific fixatives

Fluorescent in situ hybridization (FISH), 350, 351, 353

Foam cells, 242, 247,

Folic acid deficiency, 79, 87, 91

Follicle-stimulating hormone (FSH), 76, 77, 79
Follicular carcinoma, 286
Follicular cells, 304
Follicular cervicitis, 79, 85, 109
Follicular cysts, 297
Follicular cytolysis, 111
Follicular gastritis, chronic, 199
Follicular lymphoma, 352
Follicular neoplasm, 289, 305
Follicular (reactive) hyperplasia, 306
Fontana stain, 199
Food contamination, 204
Formalin, 322
Fouchet method, 357

G

Gallbladder, adenocarcinoma, 298
Gartner cysts, 31
Gastric adenocarcinoma, 202, 205
Gastric epithelium, native, 202
Gastroenteric cysts, 292
Geotrichum candidum, 98
Giant cell anaplastic carcinoma, 306
Giardia lamblia, 200, 203
Glacial acetic acid, 322
Glial fibrillary acidic protein (GFAP), 349
Glioblastoma multiforme, 172, 178
Glycogen, 82
Glycoprotein, 144
Goblet cells, 302
Gomori methenamine silverstain (GMS), 140, 147, 351, 352
Gonorrhea, vulvitis, 37
Gout, 178
Granular cell tumor (myoblastoma), 87
Granuloma, 293, 296, 310
Granulomatous inflammation, 4
Granulomatous lymphadenitis, 306
Granulomatous mastitis, 246
Granulomatous thyroiditis (de Quervain), 289
Granulosa cell tumors, 298
Granulosa-theca cell tumors, 80, 83, 85, 110
Gynecomastia, 242, 248

H

Haemophilus ducreyi, 84
Hamartoma, 288, 292
Hashimoto thyroiditis, 289, 292, 304
Helicobacter pylori, 199
Hemangioma, 287
Hematoidin crystals, 82
Hepatoblastoma (HB), 303
Hepatocellular carcinoma (HCC), 4, 289, 298, 308, 309
Hepatocytes, 307
Herpesvirus, 137, 146, 204, 205

Histiocytes
carbon-laden, 141, 146
epithelioid, 143
lipid-laden, 145
multinucleated, 4
refractile golden pigment, 139
Histoplasma capsulatum, 139, 144
HMB-45, 45, 95, 115, 169, 173, 176
Hobnail adenocarcinoma of the endometrium, 97, 98
Hodgkin disease, 138, 301, 302, 304
Hormonal levels, serum, 110
HSIL
colposcopy and, 347
keratinizing variety, 90, 110
liquid-based Paps, 337
nonkeratinizing dysplasia, 90, 106, 111
Human chorionic gonadotropin, 4, 83
Human papillomavirus (HPV)
exophytic lesions, 88
flat cervical lesions, 89, 112
high-risk, 348, 349, 378, 379, 380, 381
Hybrid Capture 2 testing, 292, 349, 350
HPV viral types, 80, 82, 89, 112, 348
in situ hybridization, 92, 348
koilocytosis, 89, 98
low-risk, 348
LSIL, 98, 110, 112
parakeratosis, 78, 85
PCR, 347
probe cocktails, 92, 100, 347
prognosis, 88
progression rate, 83, 100
reserve cells, 85
Hürthle cell neoplasm, 290, 292, 304
Hyaline globules, 287
Hybrid capture 2, 92, 349, 350
Hyperchromasia, 334
Hyperchromatic crowded "chaotic" groups, 85, 105, 109
Hyperdifferentiation, 106
Hyperkeratosis, 76, 78, 85, 87, 91, 98, 112
Hypersensitivity reaction, 146

I

Idiopathic eosinophilia, 175, 179
Immature metaplasia, 78, 107, 111
Immunoblasts, 302, 305
Immunocytochemistry, 92, 138, 182, 300, 348
Infiltrating ductal carcinoma, 246
Intermediate cell atrophy, 77
Intermediate-like cells, 89
International Classification of Diseases-9 (ICD-9), 371
Intestinal metaplasia, 203, 205
Intracytoplasmic inclusions, 79

Intranuclear cytoplasmic inclusions (INCLs), 308
Intrauterine devices (IUDs), 82, 86, 95, 99
Invader (cleavage-based) amplification, 349, 350
Iron stain, 169, 351
Irradiation. *see* Radiation therapy.
Islet cell tumor of the pancreas, 301

J

Janus green, 352
Juvenile papillomatosis, 240

K

Kaposi sarcoma, 308
Karyolysis, 81
Karyomegaly, 90, 91
Karyorrhexis, 81
Keratin. *see also* specific tumors
high-molecular weight, 179, 350, 352
pearls, 172
staining for, 353
Keratinization, 91, 338
Keratinizing dysplasia, 91
Ki-67, 350
Kite cells, 89
Koilocytes, 81, 107
Koilocytosis, 88
Krukenberg tumor, 198
Kupffer cells, 4

L

Lactating adenoma, 244, 246
Lactic acid, 103
Lactobacillus acidophilus, 80, 99, 103
Large cell carcinoma, 137, 290
Large cell cleaved lymphoma, 143, 300, 302, 306
Large cell lymphoma, 202, 203, 300, 302
LEEP/LLETZ treatment, 379
Leiomyosarcoma, 4, 84, 104, 199
Leishmania sp., 297
Leptomeningeal cells, 170
Leptothrix vaginalis, 98
Leu-M1, 4, 299
Leukocyte common antigen, 144, 180, 352
Leukoplakia, 98
Licensure, 369
Lichen sclerosus, 87
Lipid pneumonia, 141
Lipoid pneumonia, 140
Lipoma, 4, 245, 307
Lipophagic granuloma, 305
Liposarcoma, 295
Liquid-based Pap preparations, 321

Lithium carbonate, 323
Liver, 78, 289. *see also* Hepatocellular carcinomas (HCC)
Lobular carcinoma, 240, 244, 247, 300, 303
Lobules, breast, 241
LSIL, 102, 110, 112, 337
Lubricant jelly, 99
Lungs
 cancer, etiologic agents, 138
 metastatic carcinoma, 169, 172, 242
 small-cell carcinoma, 179
Luteal cysts, 295
Luteal phase, 76
Luteinizing hormone (LH), 76
Lymph node hyperplasia, 299
Lymphadenitis, 301, 309
Lymphatic channels, 5
Lymphocytes, 4, 140, 297, 298, 300
Lymphoepithelial cysts, benign, 286
Lymphoid cells, polymorphic, 299, 300
Lymphoma, 85, 201, 203, 292, 293, 305
Lymph, 85
Lynch syndrome, 352

M

Macrocytes, 89
Macrocytic changes, 79, 90, 108
Macrophages, 145, 173, 177
Macula adherens, 4
Malignancy, 109, 241
Malignant mixed tumors, 286
Mallory bodies, 289
Masson trichrome, 348
Mastitis, 244
Material safety data sheets, 319
Maturation indices, 78
Meat (striated muscle) contamination, 146
Medullary carcinoma, 240, 246, 288, 289
Medulloblastoma, 170, 171, 178
Megakaryocytes, 176
Melanin stains, 96, 349
Melanoma
 characteristics, 176
 malignant, 96, 173
 metastatic, 169, 292, 305, 353
Meningioma, 4, 170, 179
Meningitis, 172, 178, 179
Menses, 77, 101
Menstrual cycle, 101
Merkel cell tumor, 179
Mesenchymal repair, 297
Mesoderm, 81
Mesothelial cells, 173, 174, 177, 178, 179, 309, 338
Mesothelioma, 146, 174, 175, 176, 180
Metaplastic cells, 92, 103, 111, 145, 200
Metaplastic dysplasias
 immature, frequency of, 92

 nonkeratinizing, 200
 progression rate, 92
Metastatic carcinoma, 92, 199, 287
Methanol, 322, 323
Methyl green pyronine (MGP), 347
Microbacteria, 137
Microcystic adenoma, 300
Microductal carcinoma in situ (DCIS), 241
Microglandular hyperplasia, 77, 109
Microphthalmia-associated transcription factor (MITF), 96, 137, 173, 176
Microsatellite instability, 352
Microvilli, 5
Mikulicz disease, 293
Mitotic figures, 76, 92, 173
Mixed mesodermal tumor, 113
Mixed müllerian tumors, 86, 93, 103, 113, 291
Molluscum contagiosum, 101
Monomorphic adenoma, 287
Monosodium urate crystals, 169, 178
Mosaic patterns, 88
Mott cells, 180
Mucicarmine, 145, 181, 246, 352, 353
Mucinous cystadenocarcinomas (MCA)
 ovarian, 83
 primary, 297
Mucinous cystic tumors, 298
Mucin, 347
Mucoepidermoid carcinoma, 287, 304
Müllerian tumor, 81, 93
Multinucleated histiocytes, 4
Myelogenous leukemia, 4
Multiple sclerosis, 170
Mycobacterium avium-intracellulare, 143
Myelogenous leukemia, 4
Myofibroblasts, radio therapy and, 93

N

National Labor Relations Act, 365
Navicular cells, 82, 103
Neural sheath tumors, 292
Neuroblastoma, 171, 351
Neuroendocrine differentiation, 5
Neuroendocrine tumors, 142
Nile blue sulfate, 351
Nitric acid, 319
Nocardia asteroides, 4, 139
Non-Hodgkin lymphoma, 143, 288
Nonkeratinizing dysplasia
 moderate, 92
 severe, 104
Nontrabecular hepatocellular carcinoma, 289
Normochromasia, cytoplasmic streaming, 82
Nosedrops,
 Nose inhalant abuse, 145
Nuclear-to-cytoplasmic ratios, 80, 90, 110, 336, 338

Nucleic acid analysis, 92
Nucleopore filters,
 Nulliparity, 83, 85

O

Oat cell carcinoma, 142
Occupational Safety and Health Administration OSHA, 370
oil red O, 140
Oncocytic neoplasms, 295
Oncocytic neuroendocrine carcinoma of the pancreas, 302
Oncocytoma, 287
Oncogene activation, 83
Oral contraceptives, 77
Orangeophilia, 107, 109, 143, 338
Osteoarthritis, 169
Osteoblastoma, 294
Osteosarcoma, 81, 93, 295
Other category, 377
Ovarian tumors
 adenocarcinoma, mucinous, 88, 92, 114, 176
 cystadenocarcinoma, mucinous, 86
 serous adenocarcinoma, 84, 88

P

p16, 351
Paget disease, 81, 95, 242, 243
Pan-B cell surface antigens, 299
Pancreas
 anaplastic carcinoma, 299
 pancreatitis, acute, 311
Pancreaticobiliary carcinoma, 180
Pancreatitis, 298, 299
Papillary carcinoma of the thyroid, 303
Papillary carcinoma, 94, 113, 114, 288, 303, 304, 306
Papillary clusters, 94, 170, 247
Papillary neoplasms, 83
 rule out carcinoma, 241
Papilloma, 170, 243
Parabasal cells, 85, 88, 99
Paragonimus westermani, 174
Parakeratosis, 77, 78, 87, 91, 98, 139
Paramesonephric duct system, 83
Parenchyma, normal, 311
Pareto diagrams, 366
Parietal cells, 201
PAS, 172, 174, 175, 198, 204, 295, 352, 352, 353
PAS-D, 173
Patient histories, 175
Pemphigus vulgaris, 79, 110
Perimenarche, 100
Pernicious anemia, 200
Peutz-Jeghers syndrome, 198, 200
Pharynx, non-pulmonary cells from, 143
Pheochromocytoma, 296

Phyllodes tumor, 243, 248
 Pigment, 139
 Pineoblastoma, 170
 Pituitary gland,
 gonadotropins, 76
 Plant material, 141, 147, 294
 Plasma cells, 5, 87, 300, 302, 306
 Plasma thrombin method, 319
 Plasmacytoma, 293
 Pleocytosis, reactive, 171
 Pleomorphic adenoma, 293, 294, 310
 Pleomorphism
 endocervical adenocarcinoma, 95
 keratinizing processes, 81, 106, 112
 squamous cell carcinoma, 94, 107
 Pleuro-esophageal fistula, 177
 Plummer-Vinson syndrome, 201
Pneumocystis carinii, 140, 145, 147,
 292, 309, 351
 Pneumocytes, type II,
 Pneumothorax, 292
 Pollen contamination, 99, 146
 Polka dots, 89
 Polychromasia, 79
 Polyethylene glycol, 322, 323
 Polylysine coated slides, 319
 Polymerase chain reaction (PCR), 347,
 348
 Polymorphous low-grade primary, 287
 Postmenopausal women, 77, 81, 87,
 101, 103
 Post-oil myelogram, 171
 Post-irradiation dysplasia, 109
 Pouch of Douglas, 102
 Progesterone therapy, 78, 96, 101
 Prostate gland
 adenocarcinoma, 172, 182, 291,
 306
 hyperplasia, 182, 299
 Prostate-specific antigen (PSA), 172,
 182, 294
 Psammoma bodies, 80, 84, 94, 113,
 142
 Pseudoinclusions, 4
 Pseudokeratosis, 89
 Pseudolymphoma, 203
 Pyknosis, 77, 81

R

Radiation therapy, 90, 94, 95, 102, 105,
 106, 108, 294
 Radiosensitivity, 83
 Rakoff method, 352
 Reactive lymph node hyperplasia
 (RLNH), 179, 301
 Reactive lymphocytosis, 177
 Reactive/repairative changes
 bronchial cells, 141, 144
 colonic brushing, 202
 duodenal specimens, 203
 esophageal brushings, 145, 204

FNA, 299, 309
 gastrointestinal specimens, 202
 secondary to ulcerative colitis, 205
 Reiter syndrome, 172
 Renal cell carcinoma, 175, 303
 Reparative/regenerative processes
 colonic brushings, 200
 differentiation from malignancy, 79
 endocervical, 96, 105, 111, 112
 esophageal, 205
 gastrointestinal specimens, 198,
 200, 202, 204
 histology, 105
 squamous, 82, 101, 105, 110, 111
Res ipsa loquitur, 354
 Reserve cell hyperplasia (RCH), 81, 91,
 140, 144
 Reserve cells, 81, 89, 91
Respondet superior, 365, 366
 Retinoblastoma, 81, 171
 Retrospective reviews, 80
 Rhabdomyosarcoma, 81, 93, 97, 113
 Rheumatoid arthritis, 169, 180
 Rheumatoid pleuritis, 175, 181
 RNA-DNA hybrids, captured, 348
 Romanovsky stain, 147, 290, 347, 353
 rosebud, 391

S

S-100 stain, 92, 95, 137, 169, 173, 176,
 181, 351
 Saccomanno technique, 142, 321
 Saponin method, 323
 Sarcoidosis, 301
 Sarcoma, 5
 Schiller test, 80
 Schwannoma, 171, 294
 Scleroderma, 176
 Secretory ductal carcinoma, 310
 Secretory granules, 5
 Secretory phase, menstrual cycle, 76
 Seminoma, 295, 297, 307
 Serotonin, 242
 Serous adenocarcinomas. *see also*
 specific organs
 serous cystadenocarcinoma, 84,
 94, 297
 Sertoli-Leydig cell tumors, 76, 95
 Shorr method, 352
 Sialadenitis, 293
 Siderophages, 139, 145, 177
 Signet ring morphology, 201, 286
 Siliac acid, 319
 Sjögren syndrome, 293
 Small cell carcinoma. *see also* specific
 organs
 bronchial brushings, 181
 chromogranin, 143
 FNA, 291
 metastatic, 174, 181
 neuroendocrine, 92, 93
 oat cell variety, 137
 Small cell carcinoma in situ, 5, 91, 107
 Small cell non-cleaved lymphoma, 300,
 301, 302
 Small round cell lymphoma, 300, 302
 Sort rates, 319
 "Spillup" kits, 320
 Sputum specimens,
 Squamous carcinoma in situ (CIS), 105,
 107, 310
 Squamous cell carcinoma. *see also*
 specific organs
 conventional and liquid-based
 Paps, 337
 cytology, 94, 101, 104
 FNA, 291
 high-molecular-weight keratin,
 350
 keratinizing type, 91, 101, 106,
 139, 200, 204
 metastatic, 200, 310, 353
 nonkeratinizing, 91, 94, 104, 202,
 337
 poorly differentiated, 137, 142
 Squamous cells, 91, 101, 140
 Squamous dysplasia, 95, 107, 140
 Squamous epithelial lesions, 105, 106
 Squamous intraepithelial neoplasia/
 carcinoma in situ, 105
 Squamous metaplasia, 86, 105, 106,
 109, 139, 142
Staphylococcus aureus, 93
 Starch granulomatosis, 146, 296
 Steatorrhea, 203
 Stein-Leventhal syndrome (SLD), 79,
 101, 110
 Stomach, 169
 Strand displacement amplification, 348
 Stratum corneum, 78
 Strawberry cervix, 82, 104
 Stromal elements, 95
 Subdural hematoma, 169
 Sudan black, 140, 351
 Synaptophysin, 92
 Syncytial-like aggregates, 85, 93, 109
 Syncytiotrophoblasts, 76, 83
 Synovial lining cells, reactive, 181
 Synovial sarcoma, 171
 Systemic lupus erythematosus (SLE),
 174, 180

T

T-cell surface antigens, 299
Terminal deoxytransferase, 178
Thionin blue, 319
Thymoma, invasive, 293
Thyroid gland, 176, 286
Toluidine blue, 319, 324
Torulopsis glabrata, 78, 97
Toxoplasma gondii, 173
Transformational cell zones, 106
Transitional cell carcinoma, 308
Trichomonas sp.
 infection, 77, 78, 200
 vaginal/cervical scrape specimen,
 104
 vaginalis, 77, 82, 98, 101
Trophoblasts, reactive, 82
Tubal metaplasia (TM), 84, 113
Tuberculosis, 177
Tubularcarcinoma, 245
Turner syndrome, 77, 100, 104, 111
Tzanck test, 79

U

Ulcerative colitis, 198
Uterus, congenital absence, 112

V

Vacuoles, 81, 86
Vaginal adenosis, 76
Vascular channels, 5
Vascular invasion, 288
Vascular lesions, 290
Vegetable contamination, 4, 198, 201,
204
Vimentin, 174, 352
Viral infection, 146
Vitamin A deficiency, 94
Vitamin B deficiency, 94
Vitamin C deficiency, 94

W

Warning labels, 321
Warthin tumor, 287, 310
White blood cells, 334
Wilms tumor, 175, 182

Y

Yellow slides, 323
Yolk sac tumor, 296

Z

Ziehl-Neelsen stain, 143